
|Articles|April 1, 2008
A shot in the dark: Safety, efficacy, research lacking for pediatric medications
Pediatric dermatologist Elaine Siegfried, M.D., says that, about 80 percent of the time, she has to treat patients with drugs that have no FDA-approved indication or have never been formally studied in children.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
3
Comparative Analysis Positions Zasocitinib Among Next-Generation TYK2 Inhibitors
4
Off-Label Case Series: Topical Roflumilast for Mild HS
5


















